Teva Pharmaceuticals Presents Data Showing Healthcare Providers Prioritize Drowsiness Risk, Long-Term Response And Drug Interactions When Treating Older TD Patients
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia
Teva shared data showing what doctors care about most when picking tardive dyskinesia medicine. This tells us what features matter to doctors and how they decide on treatments.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.